CBM focuses on control of pathogenic bacteria, in particular opportunistic pathogenic bacteria which cause chronic infections. These bacteria live as biofilm communities and they have become evident in environmental, industrial, and medical problems. NIH estimates biofilms are involved in 60% of all bacterial infections. Biofilms can withstand the action of the immune system and tolerate the highest deliverable doses of antibiotics. At the present, biofilm infections cannot be efficiently treated.

Biofilm infections are becoming more and more common with the increase in aging population and the concomitant use of artificial organs and joints which create ideal environments for a biofilm based infection.

CBM therefore addresses a very important problem in society which at the moment no other Danish institution deals with.

The aim is to devise new anti-bacterial strategies and develop “intelligent” treatment scenarios for medical and industrial purposes and educate civil engineers and PhD’s with expertise in the field of biomedical engineering.

Understand biofilm biology
Develop anti-biofilm drugs with high target specificity
No development of resistance
No effect on beneficial flora
Natural prophylaxis and treatment against chronic infections.